Cat.NO.:A648741 Purity:99%
Product Details of [ 10025-69-1 ]
| CAS No. : | 10025-69-1 |
| Formula : |
Cl2H4O2Sn |
| M.W : |
225.65
|
| SMILES Code : | [Sn+2].[Cl-].[Cl-].[H]O[H].[H]O[H] |
| MDL No. : | MFCD00149863 |
Safety of [ 10025-69-1 ]
| GHS Pictogram: | ![]() |
| Signal Word: | Danger |
| Hazard Statements: | H302+H332-H314-H317-H373-H410 |
| Precautionary Statements: | P260-P273-P280-P303+P361+P353-P304+P340+P310-P305+P351+P338-P391 |
| Class: | 8 |
| UN#: | 3260 |
| Packing Group: | Ⅲ |
Computational Chemistry of [ 10025-69-1 ] Show Less
Physicochemical Properties
| Num. heavy atoms | 5 |
| Num. arom. heavy atoms | 0 |
| Fraction Csp3 | None |
| Num. rotatable bonds | 0 |
| Num. H-bond acceptors | None |
| Num. H-bond donors | None |
| Molar Refractivity | 23.56 |
| TPSA ?
Topological Polar Surface Area: Calculated from |
18.46 Ų |
Lipophilicity
| Log Po/w (iLOGP)?
iLOGP: in-house physics-based method implemented from |
None |
| Log Po/w (XLOGP3)?
XLOGP3: Atomistic and knowledge-based method calculated by |
None |
| Log Po/w (WLOGP)?
WLOGP: Atomistic method implemented from |
None |
| Log Po/w (MLOGP)?
MLOGP: Topological method implemented from |
None |
| Log Po/w (SILICOS-IT)?
SILICOS-IT: Hybrid fragmental/topological method calculated by |
None |
| Consensus Log Po/w?
Consensus Log Po/w: Average of all five predictions |
None |
Water Solubility
| Log S (ESOL):?
ESOL: Topological method implemented from |
None |
| Solubility | None mg/ml ; None mol/l |
| Class?
Solubility class: Log S scale |
None |
| Log S (Ali)?
Ali: Topological method implemented from |
None |
| Solubility | None mg/ml ; None mol/l |
| Class?
Solubility class: Log S scale |
None |
| Log S (SILICOS-IT)?
SILICOS-IT: Fragmental method calculated by |
None |
| Solubility | None mg/ml ; None mol/l |
| Class?
Solubility class: Log S scale |
None |
Pharmacokinetics
| GI absorption?
Gatrointestinal absorption: according to the white of the BOILED-Egg |
None |
| BBB permeant?
BBB permeation: according to the yolk of the BOILED-Egg |
None |
| P-gp substrate?
P-glycoprotein substrate: SVM model built on 1033 molecules (training set) |
None |
| CYP1A2 inhibitor?
Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) |
None |
| CYP2C19 inhibitor?
Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) |
None |
| CYP2C9 inhibitor?
Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) |
None |
| CYP2D6 inhibitor?
Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) |
None |
| CYP3A4 inhibitor?
Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) |
None |
| Log Kp (skin permeation)?
Skin permeation: QSPR model implemented from |
None cm/s |
Druglikeness
| Lipinski?
Lipinski (Pfizer) filter: implemented from |
None |
| Ghose?
Ghose filter: implemented from |
None |
| Veber?
Veber (GSK) filter: implemented from |
None |
| Egan?
Egan (Pharmacia) filter: implemented from |
None |
| Muegge?
Muegge (Bayer) filter: implemented from |
None |
| Bioavailability Score?
Abbott Bioavailability Score: Probability of F > 10% in rat |
None |
Medicinal Chemistry
| PAINS?
Pan Assay Interference Structures: implemented from |
None alert |
| Brenk?
Structural Alert: implemented from |
None alert: heavy_metal |
| Leadlikeness?
Leadlikeness: implemented from |
No; 1 violation:MW< td=””> |
| Synthetic accessibility?
Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) |
None |
Application In Synthesis of [ 10025-69-1 ]
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
- Downstream synthetic route of [ 10025-69-1 ]










Reviews
There are no reviews yet.